Vilazodone
Viibryd, Vilazodone (vilazodone) is a small molecule pharmaceutical. Vilazodone was first approved as Viibryd on 2011-01-21. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and 5-hydroxytryptamine receptor 1A. In addition, it is known to target histamine H1 receptor, D(3) dopamine receptor, D(2) dopamine receptor, and 5-hydroxytryptamine receptor 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Viibryd, Vilazodone
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| viibryd | New Drug Application | 2023-10-17 |
| vilazodone | NDA authorized generic | 2024-06-05 |
| vilazodone hydrochloride | ANDA | 2024-09-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| major depressive disorder | EFO_0003761 | D003865 | F22 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 5 | 9 | 7 | — | 21 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 5 | 9 | 7 | — | 21 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 4 | 9 | 7 | — | 20 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 3 | 1 | 1 | 5 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | 1 | — | 3 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | 1 | — | 1 |
| Morbidity | D009017 | — | — | — | — | — | 1 | — | 1 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | 1 | — | 1 |
| Separation anxiety | D001010 | EFO_1001916 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Traumatic stress disorders | D040921 | — | — | — | 2 | — | — | — | 2 |
| Memory disorders | D008569 | — | — | — | 1 | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | — | — | — | — | 1 | 1 |
| Hot flashes | D019584 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vilazodone |
| INN | vilazodone |
| Description | Vilazodone is a 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder. It has a role as an antidepressant, a serotonergic agonist and a serotonin uptake inhibitor. It is a member of indoles, a nitrile, a N-arylpiperazine, a N-alkylpiperazine, a member of 1-benzofurans and a monocarboxylic acid amide. It is a conjugate base of a vilazodone(1+). |
| Classification | Small molecule |
| Drug class | Serotonin modulator |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1 |
Identifiers
| PDB | — |
| CAS-ID | 163521-12-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL439849 |
| ChEBI ID | 70707 |
| PubChem CID | 6918314 |
| DrugBank | DB06684 |
| UNII ID | S239O2OOV3 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A4
SLC6A4
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Vilazodone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 996 documents
View more details
Safety
Black-box Warning
Black-box warning for: Viibryd, Vilazodone, Vilazodone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,210 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use